Octagon Capital Advisors as of March 31, 2021
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 28 positions in its portfolio as reported in the March 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| I Mab Sponsored Ads (IMAB) | 9.7 | $26M | 530k | 48.47 | |
| Curis Com New | 9.1 | $24M | 2.1M | 11.32 | |
| Apellis Pharmaceuticals (APLS) | 8.9 | $24M | 548k | 42.91 | |
| 4d Molecular Therapeutics In (FDMT) | 6.2 | $16M | 378k | 43.38 | |
| Acceleron Pharma | 5.7 | $15M | 112k | 135.61 | |
| Gossamer Bio (GOSS) | 4.9 | $13M | 1.4M | 9.25 | |
| Arvinas Ord (ARVN) | 4.4 | $12M | 179k | 66.10 | |
| Celldex Therapeutics Com New (CLDX) | 4.4 | $12M | 561k | 20.60 | |
| Ikena Oncology (IKNA) | 4.3 | $11M | 400k | 28.25 | |
| Arcus Biosciences Incorporated (RCUS) | 4.2 | $11M | 400k | 28.08 | |
| Avidity Biosciences Ord (RNA) | 3.7 | $9.7M | 447k | 21.81 | |
| Dyne Therapeutics (DYN) | 3.4 | $9.1M | 584k | 15.53 | |
| Pmv Pharmaceuticals (PMVP) | 3.1 | $8.2M | 250k | 32.89 | |
| Chemocentryx | 2.9 | $7.7M | 150k | 51.24 | |
| Design Therapeutics (DSGN) | 2.8 | $7.5M | 250k | 29.90 | |
| Connect Biopharma Hldgs Ads (CNTB) | 2.6 | $6.9M | 374k | 18.50 | |
| Taysha Gene Therapies Com Shs (TSHA) | 2.5 | $6.5M | 320k | 20.30 | |
| Cardiff Oncology (CRDF) | 2.3 | $6.0M | 650k | 9.26 | |
| Ngm Biopharmaceuticals (NGM) | 2.2 | $5.8M | 200k | 29.07 | |
| Revolution Medicines (RVMD) | 2.2 | $5.8M | 126k | 45.88 | |
| Kronos Bio (KRON) | 1.6 | $4.3M | 146k | 29.27 | |
| Iveric Bio | 1.6 | $4.2M | 680k | 6.18 | |
| Merus N V (MRUS) | 1.6 | $4.2M | 200k | 20.89 | |
| Helix Acquisition Corp Com Cl A | 1.5 | $4.1M | 400k | 10.20 | |
| Edgewise Therapeutics (EWTX) | 1.5 | $4.1M | 125k | 32.50 | |
| Prometheus Biosciences | 1.4 | $3.7M | 200k | 18.26 | |
| Jiya Acquisition Corp Com Cl A | 1.1 | $3.0M | 300k | 9.84 | |
| Foghorn Therapeutics (FHTX) | 0.3 | $911k | 69k | 13.18 |
